Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers

Summary

The purpose of the trial is to evaluate the effect upon immune system of two regimens of preventive HIV vaccination in healthy adult volunteers. Volunteers will be vaccinated by DNA-C and NYVAC-C vaccines, and the immune changes will be assessed, as well as safety of the vaccines. Volunteers will be followed during 72 weeks.

Timeline

Start

2007-07

Primary completion

2008-12

Completion

2009-10

Outcome

Met primary endpoint

paper than in the 2xDNA (15; 22%) arms (primary endpoint; P = 0.047) PMID 32589686 ↗

Publications

• Results Levy Y, Lacabaratz C, Ellefsen-Lavoie K, Stohr W, Lelievre JD, Bart PA, Launay O, Weber J, Salzberger B, Wiedemann A, Surenaud M, Koelle DM, Wolf H, Wagner R, Rieux V, Montefiori DC, Yates NL, Tomaras GD, Gottardo R, Mayer B, Ding S, Thiebaut R, McCormack S, Chene G, Pantaleo G. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial. PLoS Pathog. 2020 Jun 26;16(6):e1008522. doi: 10.1371/journal.ppat.1008522. eCollection 2020 Jun.

Drugs

Indications